PSTXライブシグナル | Getagraph.comで利益を最大化

買う 108041 min ago

@ $3.72

発行日: 15 2月 2024 @ 01:00

リターン: -38.84%

前回のシグナル: 2月 14 - 05:15

前回のシグナル: 売る

リターン: 1.36 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Stats
本日の出来高	135 242
平均出来高	726 238
時価総額	219.51M
EPS	$0 ( 2024-03-14 )
次の収益日	( $-0.340 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.660
ATR14	$0.00500 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Rizvi Syed Ali-aamir	Buy	250 000	Employee Stock Option (Right to Buy)
2024-04-01	Rizvi Syed Ali-aamir	Buy	185 000	Common Stock
2024-04-01	Rizvi Syed Ali-aamir	Buy	0
2024-03-01	Mylet Johanna	Buy	80 743	Common Stock
2024-03-01	Mylet Johanna	Sell	18 091	Common Stock

INSIDER POWER
88.72
Last 92 transactions
Buy: 9 056 534 \| Sell: 550 582

ボリューム相関

長: -0.31 (neutral)

短: 0.04 (neutral)

Signal:(70.454) Neutral

Poseida Therapeutics, 相関

10 最も正の相関
EUSGU	0.901
CVCY	0.897
AGNCM	0.884
MTRX	0.88
RING	0.879
TBNK	0.877
DOOO	0.875
VIOT	0.873
WINC	0.865
GTH	0.862

10 最も負の相関
FAIL	-0.85
LLNW	-0.825
MBCN	-0.81

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Poseida Therapeutics, 相関 - 通貨/商品

0.78
( moderate )

0.76
( moderate )

0.00
( neutral )

0.59
( weak )

0.00
( neutral )

0.02
( neutral )

Poseida Therapeutics, 財務諸表

Annual	2023
収益:	$64.70M
総利益:	$64.70M (100.00 %)
EPS:	$-1.370

FY	2023
収益:	$64.70M
総利益:	$64.70M (100.00 %)
EPS:	$-1.370

FY	2022
収益:	$130.36M
総利益:	$125.19M (96.03 %)
EPS:	$-0.890

FY	2021
収益:	$31 238.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00201

Financial Reports:

No articles found.

Poseida Therapeutics,

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.